Company profile for Tessera Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tessera Therapeutics is a biotechnology company pioneering Gene Writing™, a novel genome engineering technology designed to write therapeutic messages into the genome to treat diseases at their source. The mission is to cure diseases by writing in the code of life, expanding the possibilities in genetic medicine. Gene Writing™ is a versatile platform capable of making permanent, precise alterations to the human genome, add...
Tessera Therapeutics is a biotechnology company pioneering Gene Writing™, a novel genome engineering technology designed to write therapeutic messages into the genome to treat diseases at their source. The mission is to cure diseases by writing in the code of life, expanding the possibilities in genetic medicine. Gene Writing™ is a versatile platform capable of making permanent, precise alterations to the human genome, addressing major unmet medical needs with potentially curative and accessible therapies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
55 Cambridge Parkway, Suite 800 East, Cambridge, MA 02142
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/09/3202274/0/en/Tessera-Therapeutics-Announces-Chief-Financial-Officer-CFO-Transition-and-Appointment-of-Kathy-Bergsteinsson-as-CFO.html

GLOBENEWSWIRE
09 Dec 2025

https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-tessera-therapeutics-jointly-develop-tsra-196

PRESS RELEASE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/03/3179383/0/en/Tessera-Therapeutics-to-Present-New-Preclinical-Data-From-In-Vivo-Programs-for-Sickle-Cell-Disease-and-T-Cell-Therapies-at-the-67th-American-Society-of-Hematology-Annual-Meeting.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/08/3163551/0/en/Tessera-Therapeutics-Awarded-up-to-41-3-Million-from-ARPA-H-to-Advance-In-Vivo-CAR-T-Therapies.html

GLOBENEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2025/05/17/3083480/0/en/Tessera-Therapeutics-Features-New-Preclinical-Data-Demonstrating-Progress-Across-its-In-Vivo-Gene-Writing-Programs-and-Delivery-Platform-at-the-American-Society-of-Gene-and-Cell-Th.html

GLOBENEWSWIRE
17 May 2025

https://www.globenewswire.com/news-release/2025/04/28/3069685/0/en/Tessera-Therapeutics-to-Present-New-Data-Across-Preclinical-Programs-for-its-Gene-Writing-and-Delivery-Platforms-at-the-American-Society-of-Gene-and-Cell-Therapy-28th-Annual-Meetin.html

GLOBENEWSWIRE
28 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty